A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Are 20 years or older and considered to be candidates for systemic or phototherapy.
\[Moderate to Severe Plaque Psoriasis\]
Diagnosed for at least 12 months.
Have Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis covering at least 10% of body surface area (BSA).
\[Psoriatic Arthritis\]
Diagnosed for at least 6 months.
Meet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at screening;
Have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and active plaque psoriasis with at least 2 cm in diameter.
You may not be if
Non-plaque or drug induced forms of psoriasis
Cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic arthritis or cannot discontinue phototherapy (PUVA or UVB)
any uncontrolled significant medical condition
Clareo Health | A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
